The state of Indiana and the city of Bloomington announced that Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has commenced a significant expansion of its biologics manufacturing operations in Bloomington, with plans to create up to 200 new jobs by the end of 2024.
“Indiana is the second largest exporter of life sciences products in the U.S. and is recognized as a world leader in the industry because of companies like Catalent,” Governor Eric J. Holcomb said. “This expansion is yet another example of how Indiana’s pro-business environment and skilled workforce deliver the resources that life science companies need to compete in the global marketplace. With the expansion of Catalent’s packaging and manufacturing capabilities, the company will increase its operations while creating high-tech careers for Hoosiers.”
The company is making significant investments in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers. As part of this expansion, Catalent plans to invest over $100 million in its Bloomington operations, growing the site’s packaging capabilities and manufacturing capacity to support customers’ clinical pipeline and commercial launches.
To begin, Catalent is investing nearly $14 million to expand its Biologics packaging capabilities and capacity, renovating 15,000 square feet of its facility, which will include five new packaging suites and a new quality control laboratory. Construction is due to be completed in April 2019, with installation and commissioning of new equipment to be phased throughout the year. Additionally, the company will increase fill/finish capacity in Bloomington by 79,000 square feet, installing a high-speed vial line, utilizing both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas.
“Catalent continues to make significant investments in our Bloomington facility and workforce to meet the growing demand for the world-class biologic drug development, manufacturing and packaging services we offer to global pharmaceutical companies,” commented Ryan Hawkins, General Manager, Catalent Biologics Bloomington. “We appreciate the strong relationship forged with our state and local government partners and are already hiring for dozens of open positions as we ramp up operations.”
Catalent, which employs 900 people in Bloomington, expects to create the new jobs to support increased packaging operations and growing manufacturing operations in Indiana. Interested applicants can learn more and apply online at www.biologicsjobs.com.
"We are thrilled that Catalent has announced plans to expand their manufacturing capacity and add 200 more good-paying jobs in Bloomington,” said Bloomington Mayor John Hamilton. “This investment helps confirm Bloomington’s burgeoning role within the global biotech industry and reflects confidence in the outstanding workforce and quality of life in our area.”
Catalent, which acquired Cook Pharmica in 2017, operates an 875,000 square foot biologics development and manufacturing facility in Bloomington. The operation has deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges. The site also recently achieved regulatory approval for a twentieth commercial product.
The Indiana Economic Development Corporation has offered Catalent up to $2.4 million in conditional tax credits based on the company's job creation plans. These tax credits are performance-based, meaning until Hoosiers are hired, the company is not eligible to claim incentives. The city of Bloomington is considering additional incentives at the request of the Bloomington Economic Development Corporation.